Identifying different types of severe asthma
Identification of Asthma Phenotypes in Severe Asthmatics
This study is trying to understand the different types of severe asthma in hard-to-treat patients to find better ways to manage their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 21 Years to 80 Years |
| Sex | All |
| Sponsor | Singapore General Hospital Academic / other |
| Locations | 1 site (Singapore) |
| Trial ID | NCT01623089 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the phenotypes of patients with severe asthma, focusing on those who are difficult to treat. By collecting demographic, clinical, and inflammatory data, the researchers seek to understand the various presentations and responses to treatment among this population. The study will analyze factors such as triggers, physiological characteristics, and inflammatory profiles to tailor future treatments more effectively. The ultimate goal is to improve asthma control and reduce healthcare costs associated with severe asthma.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with difficult-to-treat severe asthma who are poorly controlled despite high-dose inhaled corticosteroids or other combination therapies.
Not a fit: Patients with mild to moderate asthma or those who do not have treatment-resistant severe asthma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with severe asthma.
How similar studies have performed: Other studies have shown success in identifying asthma phenotypes, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Difficult-to-treat severe asthma 2. Treatment-resistant severe asthma patients who are partially or poorly controlled despite high dose inhaled corticosteroids ( ICS) or a high-dose ICS and long acting- beta-2- agonist combination ( LABA) and frequent or chronic use of systemic corticosteroids or 3. Treatment-resistant severe asthma who are well-controlled on the highest level of recommended treatment to maintain control (high dose ICS or combination of high-dose ICS with other medications such as LABA, theophylline, montelukast, systemic corticosteroids, anti-Ig E, etc.
Where this trial is running
Singapore
- Singapore General Hospital — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Mariko Koh, MBBS — Singapore General Hospital
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.